Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need population MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI® regimens as a potential new s
Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Wednesday, 14'th Jan 2026
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
10:00am, Wednesday, 14'th Jan 2026
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
First Look: Alphabet $4T, Nvidia China OK, Boeing Tops Airbus
07:39am, Wednesday, 14'th Jan 2026
Stock News Saks Global files Chapter 11: Saks Global (private) sought Chapter 11 protection, citing heavy debt from its 2024 Neiman Marcus deal and inventory st
Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
10:24am, Tuesday, 13'th Jan 2026
Delaware's top court overturned part of a $1 billion damages award against Johnson and Johnson in the Auris Health merger, ordering a recalculation that could lower payouts.
What's Powering J&J's MedTech Growth Ahead of Q4 Release?
08:50am, Tuesday, 13'th Jan 2026
JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.
AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines
08:09am, Tuesday, 13'th Jan 2026
AbbVie agrees to lower drug prices, invest $100 billion in the U.S., expand manufacturing, and secure tariff relief.
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
08:00am, Tuesday, 13'th Jan 2026
New CAPLYTA ® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented SPRAVATO ® (esketamine) effects on anhedonia i
Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors
02:40am, Tuesday, 13'th Jan 2026
Mar Vista's U.S. Quality strategy returned +0.20% net-of-fees in Q4 2025. The Russell 1000 Index and the S&P 500 Index returned +2.41% and +2.65%, respectively. Alphabet, Johnson & Johnson and Danaher
Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know
06:45pm, Monday, 12'th Jan 2026
Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.
Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court
06:32pm, Monday, 12'th Jan 2026
Johnson & Johnson convinced Delaware's highest court to throw out part of a $1 billion damages award for breaching its 2019 agreement to buy Auris Health, a maker of surgical robots.
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:06pm, Monday, 12'th Jan 2026
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
How Much Monthly Income Does a $2 Million Portfolio Produce at Age 60?
12:49pm, Monday, 12'th Jan 2026
At 60 years old with $2 million saved, you can safely say that you are in a good position that most people will never reach. At this point, the question in your mind should shift from whether you have
Invested Advisors Buys New Stake in Johnson & Johnson $JNJ
06:26am, Monday, 12'th Jan 2026
Invested Advisors purchased a new stake in Johnson and Johnson (NYSE: JNJ) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 6,597 shares
Birch Hill Investment Advisors LLC Sells 12,895 Shares of Johnson & Johnson $JNJ
04:00am, Monday, 12'th Jan 2026
Birch Hill Investment Advisors LLC trimmed its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 8.5% in the third quarter, according to its most recent disclosure with the Securities and Excha
